Connection
Ping-Ching Hsu to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Ping-Ching Hsu has written about Drug Resistance, Neoplasm.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.853 |
|
|
|
-
Hsu PC, Chang JW, Chiu LC, Yang CT, Kuo SC, Fang YF, Wu CE. Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy. Clin Transl Oncol. 2025 May; 27(5):1967-1979.
Score: 0.736
-
Hsu PC, Miao J, Huang Z, Yang YL, Xu Z, You J, Dai Y, Yeh CC, Chan G, Liu S, Urisman A, Yang CT, Jablons DM, You L. Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. J Cell Mol Med. 2018 06; 22(6):3073-3085.
Score: 0.117